Radnostix, Inc.

Radnostix, Inc.

INIS
Radnostix, Inc.US flagOther OTC
0.07
USD
+0.00
- -
35.03MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.02
0.02
0.02
0.02
0.02
0.03
0.02
0.02
0.02
0.02
0.02
0.03
0.02
0.02
Basic EPS, GAAP
-0.01
- -
- -
- -
-0.01
- -
- -
0.01
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
-0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.31
-0.31
-0.29
-0.29
-0.3
-0.3
-0.3
-0.29
-0.25
-0.24
-0.24
-0.23
-0.23
-0.24
Tangible Book Value per Share
- -
- -
- -
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
365
369
398
403
406
411
418
423
478
511
518
522
527
528
Sales/Revenue/Turnover
7
8
7
7
7
10
9
9
10
11
12
14
13
12
Operating Margin (%)
-30.64
-10.43
-20.41
-22.94
-27.84
-2.8
-6.23
-4.44
-7.05
-10.76
-6.33
0.05
-7.32
-18.03
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
- -
- -
- -
Net Income, GAAP
-2
-2
-2
-2
-4
-1
-2
2
-1
- -
-1
- -
-1
-2
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-35.94
-20.5
-25.75
-28.68
-50.63
-8.15
-17.01
23.52
-9.34
2.71
-7.08
0.06
-6.95
-17.55
Working Capital
2
- -
1
-4
-2
-2
-2
-2
-2
2
2
2
1
-1
LT Debt
4
3
3
- -
- -
- -
2
3
3
3
4
4
4
4
Total Equity
5
4
4
2
- -
- -
- -
3
3
4
4
4
4
3
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
-7.94
- -
-15.45
- -
0.08
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
-2.35
- -
-0.78
- -
-0.29
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
2
2
2
LT Finance Leases
3
3
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
528
528
529
Market Capitalization
31
32
44

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
5
5
4
Cash, Cash Equivalents & STI
2
2
1
Accounts Receivable, Net
2
1
1
Inventories
1
1
1
Total Current Liabilities
4
4
4
Payables & Accruals
3
3
4
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
1

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-299.48%
7.84%
-15.05%
Free Cash Flow
-362.58%
-48.4%
-204.34%
Net Income, GAAP
-1,159.09%
-2,290.47%
-10,690.18%
Sales/Revenue/Turnover
7.27%
7.19%
-5.97%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3
3
4
4
14
2025
3
4
3
3
13
2026
2
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Shahe Bagerdjian
Full Time Employees
41
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
4137 Commerce Circle Idaho Falls ID United States of America 83401
IPO Date
Aug 14, 1997
Business
International Isotopes Inc. specializes in the production and global distribution of specialized nuclear materials, including medical calibration standards, cobalt-60 offerings, and contract manufacturing for radiopharmaceutical and radiochemical applications. The company’s operations are organized across several distinct divisions: Calibration and Reference Products, Cobalt Products, Theranostics Products, Medical Devices, Radiological Services, and Fluorine Products. The Calibration and Reference Products segment crafts a comprehensive line of sources and standards essential for single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging, patient positioning, and the precise calibration and functional assessment of dose measuring equipment within the nuclear pharmacy sector. This includes items such as flood sources, dose calibrators, various rod sources, flexible and rigid rulers, along with specific spot and pen point markers. Within the Cobalt Products division, the company manufactures bulk cobalt and fabricates cobalt capsules vital for radiation therapy, diverse industrial applications, including container security examinations, and also manages the recycling of depleted cobalt sources. Notably, International Isotopes Inc. stands as the sole domestic U.S. manufacturer of high-activity Cobalt-60 sealed-source products. The Theranostics Products segment is responsible for producing and supplying a range of isotopically pure radiochemicals, including the only FDA-approved generic sodium iodide I-131 drug product made in the United States, used for treating hyperthyroidism and thyroid cancer. This segment also offers active pharmaceutical ingredient (API) supply and contract manufacturing services for external theranostics clients. A recently established Medical Devices segment, which began reporting in fiscal year 2024, is actively developing and launching new products under its RadVent brand, such as the Swirler® and Tru-Fit™ product lines, aiming to enhance safety, efficiency, and patient access in radiopharmaceutical diagnostics and therapeutics. Additionally, the Radiological Services segment provides flood source disposal and gemstone processing, alongside custom shielding and encapsulation services. The Fluorine Products division focuses on developing and producing high-purity fluoride gas samples for industrial uses, while also advancing laboratory and analytical methods to support a planned uranium de-conversion and fluorine extraction facility. The company distributes its products directly to end-users and through various distributors. Established in 1995, International Isotopes Inc. maintains its corporate headquarters in Idaho Falls, Idaho.

Company News

APIChatGPT
  • Radnostix Acquires Lucerno Dynamics Assets Expanding Radiopharma Medical Device Portfolio

  • Radnostix, Inc. Reports FY2026 Q1 Results - Revenue Declines 27% Primarily Due to Voluntary Product Recalls, Isotope Supply Disruptions, and Planned Operational Shutdown

  • Radnostix, Inc. Reports FY2025 Results - Second-Highest Annual Revenue in Company History; Delivers Strong Growth in Calibration & Reference Products and Advances Key Product Launches in 2025

  • International Isotopes (OTCMKTS:INIS) Share Price Passes Below 200-Day Moving Average – Here’s What Happened

  • International Isotopes (OTCMKTS:INIS) Stock Price Passes Above Fifty Day Moving Average – Here’s Why

  • International Isotopes (OTCMKTS:INIS) Shares Cross Below 200 Day Moving Average – Time to Sell?

  • International Isotopes (OTCMKTS:INIS) Share Price Passes Above 50 Day Moving Average – Here’s Why

  • International Isotopes Inc. Announces Company Name Change to Radnostix, Inc.

  • INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2025

  • International Assets Investment Management LLC Has $11.20 Million Position in Alphabet Inc. $GOOGL

  • INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR THE SECOND QUARTER AND SIX MONTHS ENDED JUNE 30, 2025

  • INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR THE FIRST QUARTER 2025

  • INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR 2024

  • International Isotopes, Inc. Expands Operational Footprint with Strategic Land Acquisition and Additional New Facility Lease Agreement

  • International Isotopes, Inc. Announces the Amendment of the Acquisition of the AMICI, Inc. Product Line

  • INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR THE THIRD QUARTER AND FIRST NINE MONTHS OF 2024

  • INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR THE SECOND QUARTER AND FIRST SIX MONTHS OF 2024

  • INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR THE FIRST QUARTER OF 2024

  • INTERNATIONAL ISOTOPES INC. ANNOUNCES FISCAL RESULTS FOR FISCAL YEAR 2023

  • INTERNATIONAL ISOTOPES TO DIVEST DEPLETED URANIUM DECONVERSION ASSETS TO AMERICAN FUEL RESOURCES FOR $12,500,000 CASH